These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21835956)

  • 1. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
    Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
    Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
    Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
    Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH
    Blood; 2011 Aug; 118(5):1329-39. PubMed ID: 21659544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
    Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
    Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
    Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
    Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
    Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S
    Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
    Yecies D; Carlson NE; Deng J; Letai A
    Blood; 2010 Apr; 115(16):3304-13. PubMed ID: 20197552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.